ad image

Company Info

Lonza

Lonza

CDMO

Overview

At Lonza, we enable a healthier world by supporting our healthcare customers on the path to commercialization. Our community of 16,000 skilled employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech, and nutrition markets. By combining technological insight with world-class manufacturing, scientific expertise, and process excellence, we help our customers to deliver new and innovative medicines that help treat a wide range of diseases.
Lonza
Contributions
13 Contributions1 / 1
Innovating in Automation and Data Management to Advance Microbiology
Automation

Innovating in Automation and Data Management to Advance Microbiology

Lonza

PAO-03-22-R250-06Mar 07, 2022
Advancing Drug Development with Emerging Technologies
Drug Development

Advancing Drug Development with Emerging Technologies

Lonza

PAO-02-22-R250-03Feb 03, 2022
Lonza
3D Bioprinting

Lonza and Allevi Collaborate to Advance 3D Bioprinting

Lonza

PR-M01-20-NI-012Jan 07, 2020
Challenges of Manufacturing the Expanding Range of Bi/Multispecific Modalities
Bispecific Antibody

Challenges of Manufacturing the Expanding Range of Bi/Multispecific Modalities

Bernie Sweeney

Lonza

PAP-Q4-19-CL-022Dec 06, 2019
Lonza
Agreement

Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates

Lonza

PR-M10-19-NI-006Oct 04, 2019
Lonza
Partnership

Lonza Partners with Vineti Across its Cell and Gene Therapy Manufacturing Network to Optimize 'Vein-to-Vein' Delivery Service

Lonza

PR-M08-19-NI-008Aug 02, 2019
Lonza
Growth

Lonza on Track to Deliver Full-Year 2019 Results, Driven by Pharma Biotech Business

Lonza

PR-M07-19-NI-069Jul 26, 2019
Lonza
M&A

Lonza to Acquire Sterile Fill and Finish Facility from Novartis

Lonza

PR-M07-19-NI-010Jul 05, 2019
Lonza
Partnership

Alector Opts for Lonza’s Ibex™ Develop to Secure Future Manufacturing for Neurodegeneration Therapies

Lonza

PR-M05-19-NI-032May 10, 2019
Addressing Development Challenges for Complex Biologic Drug Candidates
Biologic Candidates

Addressing Development Challenges for Complex Biologic Drug Candidates

Karen Fallen

Lonza

PAP-Q2-18-CL-004May 29, 2018
Lonza
Cell Culture Portfolio

Lonza Expands Cell-Culture Portfolio with Quasi Vivo ® System

Lonza

PR-M02-18-NI-59Feb 16, 2018
Lonza
Strategic Partnership

Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines

Lonza

PR-M02-18-NI-047Feb 14, 2018
Lonza
Research

Lonza to Present Latest Research into More Physiologically Relevant ADME-Tox Models at the Society of Toxicology Meeting

Lonza

PR-M02-18-NI-034Feb 09, 2018
1 / 1